Charis En-Yi Teh

The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival

Pasquale L Fedele, Yang Liao, Jia-nan Gong, Yuan Yao, Mark F van Delft, Michael SY Low, Lin Tai, Marco J Herold, Jacob T Jackson, Charis E Teh, Tania Tan, Lorraine A O'Reilly, Julie Tellier, George Grigoriadis, David CS Huang, Wei Shi, Stephen L Nutt, Simon N Willis

Journal article  |  2020  |  LEUKEMIA

Removing unwanted variation with CytofRUV to integrate multiple CyTOF datasets

Marie Trussart, Charis E Teh, Tania Tan, Lawrence Leong, Daniel HD Gray, Terence P Speed

Journal article  |  2020  |  ELIFE

Mass cytometry (CyTOF) is a technology that has revolutionised single-cell biology. By detecting over 40 proteins on millions of s..

MCL-1 is essential for survival but dispensable for metabolic fitness of FOXP3( )regulatory T cells

Charis E Teh, Alissa K Robbins, Darren C Henstridge, Grant Dewson, Sarah T Diepstraten, Gemma Kelly, Mark A Febbraio, Sarah S Gabriel, Lorraine A O'Reilly, Andreas Strasser, Daniel HD Gray

Journal article  |  2020  |  CELL DEATH AND DIFFERENTIATION

FOXP3+ regulatory T (Treg) cells are essential for maintaining immunological tolerance. Given their importance in immune-related d..

Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma

Michael A Dengler, Charis E Teh, Rachel Thijssen, Lahiru Gangoda, Ping Lan, Marco J Herold, Daniel H Gray, Gemma L Kelly, Andrew W Roberts, Jerry M Adams

Journal article  |  2020  |  ONCOGENE

Apoptosis-regulating BCL-2 family members, which can promote malignant transformation and resistance to therapy, have become prime..

Characterization of a novel human BFL-1-specific monoclonal antibody

Lahiru Gangoda, Charis E Teh, Michael A Dengler, Sarah A Best, Clare E Weeden, Lin Tai, Erinna F Lee, Walter D Fairlie, Kate D Sutherland, Leonard C Harrison, Daniel H Gray, Andreas Strasser, Marco J Herold

Journal article  |  2020  |  CELL DEATH AND DIFFERENTIATION

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells

Charis E Teh, Jia-Nan Gong, David Segal, Tania Tan, Cassandra J Vandenberg, Pasquale L Fedele, Michael SY Low, George Grigoriadis, Simon J Harrison, Andreas Strasser, Andrew W Roberts, David CS Huang, Garry P Nolan, Daniel HD Gray, Melissa E Ko

Journal article  |  2020  |  CELL DEATH AND DIFFERENTIATION

Multiple myeloma is an incurable and fatal cancer of immunoglobulin-secreting plasma cells. Most conventional therapies aim to ind..

Deletion of self-reactive CCR7-thymocytes in the absence of MHC expression on thymic epithelial cells

Rushika C Wirasinha, Anna Chan, Jin Yan Yap, Daniel Y Hu, Charis E Teh, Daniel HD Gray, Christopher C Goodnow, Stephen R Daley

Journal article  |  2019  |  CELL DEATH AND DIFFERENTIATION

The selection of αβ T cells in the thymus is punctuated by checkpoints at which thymocytes differentiate or undergo apoptosis. Wav..

RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

Rachel Thijssen, Mary Ann Anderson, Charis Teh, Marie Trussart, Piers Blombery, Richard Birkinshaw, Jianan Gong, Daniel Gray, David Huang, Andrew Roberts

Conference Proceedings  |  2019  |  Experimental Hematology

ENHANCING EXPRESSION OF PRO-APOPTOTIC FACTORS THROUGH INHIBITION OF HDACS DRIVES P53-INDEPENDENT SYNERGY WITH VENETOCLAX FOR THE TREATMENT OF AML

Jessica Salmon, Giovanna Pomilio, Donia Moujalled, Veronique Litalien, Sarah MacRaild, Charis Teh, Sewa Rijal, Adam Ivey, Teh T.C., Paul Ekert, Laurence Krous-Berthier, Ioana Kloos, Marie Schoumacher, Daniel Gray, Andrew Wei

Conference Proceedings  |  2019  |  Experimental Hematology

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jia-nan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella R Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E Lew, Ian J Majewski, Daniel HD Gray, David A Westerman, Constantine S Tam, John F Seymour, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2019  |  CANCER DISCOVERY

The BCL2 inhibitor venetoclax induces high rates of durable remission in patients with previously treated chronic lymphocytic leuk..